883 Expression and clinical relevance of the lung resistance protein in germ cell testicular tumours

Mándoky, László; Gergely, Lajos; Doleschall, Z.; Bodrogi, I.; Csuka, Orsolya; M, Bąk

doi:10.1016/s1359-6349(03)90909-8

Cited by 15 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinically, LRP overexpression has been associated with poor responses to chemotherapy in different malignancies such as NSCLC List et al 1996;Volm et al 1997;Raaijmakers et al 1998). Similarly, LRP has been shown to be overexpressed in a subgroup of cisplatin-resistant NSCLC cell lines (Berger et al 2000), and LRP has recently been reported to be a predictive marker for treatment response in NSCLC and testicular germ-cell tumors (Harada et al 2003;Mandoky et al 2004). However, other studies failed to detect such an association (Dingemans et al 1996), and another study showed that LRP expression in NSCLC was not enhanced in patients treated with chemotherapy (Berger et al 2005).…”

Section: Discussionmentioning

confidence: 99%

Immunolocalization and Cell Expression of Lung Resistance-related Protein (LRP) in Normal and Tumoral Human Respiratory Cells

Bouhamyia

Chantot‐Bastaraud

Zaïdi

et al. 2007

J Histochem Cytochem.

View full text Add to dashboard Cite

Lung resistance-related protein (LRP) is an integral part of the multidrug resistance (MDR) phenotype involved in cell resistance toward xenobiotics or chemotherapy. The aim of this study was to compare the intracellular localization and cell expression of LRP in normal bronchial cells and their tumoral counterparts from non-small cell lung cancer (NSCLC). LRP expression was also investigated concurrently with DNA ploidy and chromosome 16 ( lrp gene locus) aberrations. Confocal microscopy showed that LRP localization was exclusively intracytoplasmic regardless of the cell type and was never observed in the nuclear pore complex. Flow cytometry demonstrated a similar level of LRP expression in normal bronchial cells and in cancer cells from NSCLC samples. FISH analysis, performed to evaluate the number of chromosome 16 and lrp loci, demonstrated a significant gain of chromosome 16 in DNA aneuploid tumors. Furthermore, we did not find any link between LRP expression and DNA ploidy status or chromosome 16 number. These results suggest that LRP expression observed in NSCLC, maintained through the carcinogenesis process of respiratory cells, is not altered by the increased number of copies of chromosome 16 and probably controlled by mechanisms different from those of MRP1 expression, whereas both proteins are associated with the MDR phenotype. (J Histochem Cytochem 55: 773–782, 2007)

show abstract

Section: Discussionmentioning

confidence: 99%

Immunolocalization and Cell Expression of Lung Resistance-related Protein (LRP) in Normal and Tumoral Human Respiratory Cells

Bouhamyia

Chantot‐Bastaraud

Zaïdi

et al. 2007

J Histochem Cytochem.

View full text Add to dashboard Cite

show abstract

“…In advanced testicular germ-cell tumors only a subgroup of tumors stained positively for MVP, correlating with shorter progression-free and overall survival of patients [140,141]. Surprisingly, this adverse prognosis was related to MVP over-expression and advanced tumor stage but not based on reduced response to platinum-based therapy [140].…”

Section: Solid Tumorsmentioning

confidence: 98%

Cellular Functions of Vaults and their Involvement in Multidrug Resistance

Steiner

Holzmann²,

Elbling³

et al. 2006

CDT

View full text Add to dashboard Cite

Vaults are evolutionary highly conserved ribonucleoprotein (RNP) particles with a hollow barrel-like structure. They are 41 x 73 nm in size and are composed of multiple copies of three proteins and small untranslated RNA (vRNA). The main component of vaults represents the 110 kDa major vault protein (MVP), whereas the two minor vault proteins comprise the 193 kDa vault poly(ADP-ribose) polymerase (VPARP) and the 240 kDa telomerase-associated protein-1 (TEP1). Vaults are abundantly present in the cytoplasm of eukaryotic cells and they were found to be associated with cytoskeletal elements as well as occasionally with the nuclear envelope. Vaults and MVP have been associated with several cellular processes which are also involved in cancer development like cell motility and differentiation. Due to the over-expression of MVP (also termed lung resistance-related protein or LRP) in several P-glycoprotein (P-gp)-negative chemoresistant cancer cell lines, vaults have been linked to multidrug resistance (MDR). Accordingly, high levels of MVP were found in tissues chronically exposed to xenobiotics. In addition, the expression of MVP correlated with the degree of malignancy in certain cancer types, suggesting a direct involvement in tumor development and/or progression. Based on the finding that MVP binds several phosphatases and kinases including PTEN, SHP-2 as well as Erk, evidence is accumulating that MVP might be involved in the regulation of important cell signalling pathways including the PI3K/Akt and the MAPK pathways. In this review we summarize the current knowledge concerning the vault particle and discuss its possible cellular functions, focusing on the role of vaults in chemotherapy resistance.

show abstract

“…Owing to the fact that there is more pronounced expression of erbB2 in fetal or embryonic tissues, it is unexpected that there is only modest overexpression of HER2/neu in germ cell tumors and negligible gene amplification [461][462][463], >40%, in non-melanoma skin cancer [464] and in B lymphoblasts [465,466], but not in thymomas [467]. With the exceptions of the B lymphoblast, thymoma and variable sarcomas, tumors with HER2/neu overexpression arise from tissues that have been reported to have HER2/neu expression either in fetal or adult developmental stages.…”

Section: Miscellaneous Tumors With Her2/neu Overexpressionmentioning

confidence: 99%

HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

Nelson¹

2014

Clinical Investigation

View full text Add to dashboard Cite

No biological molecule in the field of oncology has been more extensively or more successfully targeted for therapeutic intent than the product of the c-erbB2 gene, HER2/neu. This is the second of a comprehensive three-part review of the foundation for and therapeutic targeting of HER2/neu. The distribution of HER2/neu overexpression and/or gene amplification by individual tumor sites and histologies will be comprehensively surveyed and described. This provides a bridge between the primarily basic science focused Part I, and the survey of clinical applications to follow in Part III. In combination, this comprehensive survey will identify opportunities and promising areas for future evaluation of HER2/neu-targeted therapies, highlighting the importance of HER2/neu as an increasingly important therapeutic target.

show abstract

883 Expression and clinical relevance of the lung resistance protein in germ cell testicular tumours

Cited by 15 publications

References 0 publications

Immunolocalization and Cell Expression of Lung Resistance-related Protein (LRP) in Normal and Tumoral Human Respiratory Cells

Immunolocalization and Cell Expression of Lung Resistance-related Protein (LRP) in Normal and Tumoral Human Respiratory Cells

Cellular Functions of Vaults and their Involvement in Multidrug Resistance

HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

Contact Info

Product

Resources

About